Eigl, B J <br/><br/>
A phase II study of the HDAC inhibitor SB939 in patients with castration resistant prostate cancer: NCIC clinical trials group study IND195.  [electronic resource] 

 -  Investigational new drugs  Aug 2015 
 - 969-76 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1573-0646 
<br/><br/><label>Standard No.: </label>10.1007/s10637-015-0252-4  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Aged, 80 and over<br/>Antineoplastic Agents--adverse effects<br/>Benzimidazoles--adverse effects<br/>Disease-Free Survival<br/>Histone Deacetylase Inhibitors--adverse effects<br/>Humans<br/>Kallikreins<br/>Male<br/>Middle Aged<br/>Neoplastic Cells, Circulating--metabolism<br/>PTEN Phosphohydrolase--genetics<br/>Prostate-Specific Antigen<br/>Prostatic Neoplasms, Castration-Resistant--blood<br/>Serine Endopeptidases--genetics<br/>Trans-Activators--genetics<br/>Transcriptional Regulator ERG